Currently, there are 191.78M common shares owned by the public and among those 106.41M shares have been available to trade.
The company’s stock has a 5-day price change of -11.35% and 20.03% over the past three months. ALHC shares are trading 55.56% year to date (YTD), with the 12-month market performance up to 253.54% higher. It has a 12-month low price of $4.90 and touched a high of $21.06 over the same period. ALHC has an average intraday trading volume of 2.69 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.11%, 6.87%, and 40.37% respectively.
Institutional ownership of Alignment Healthcare Inc (NASDAQ: ALHC) shares accounts for 56.75% of the company’s 191.78M shares outstanding.
It has a market capitalization of $3.36B and a beta (3y monthly) value of 1.29. The earnings-per-share (ttm) stands at -$0.67. The company has a debt-to-equity ratio at 3.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.89% over the week and 6.11% over the month.
Analysts forecast that Alignment Healthcare Inc (ALHC) will achieve an EPS of -0.06 for the current quarter, 0.01 for the next quarter and 0.13 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.18 while analysts give the company a high EPS estimate of -0.18. Comparatively, EPS for the current quarter was -0.12 a year ago. Earnings per share for the fiscal year are expected to increase by 42.07%, and 56.46% over the next financial year. EPS should grow at an annualized rate of 62.27% over the next five years, compared to -22.95% over the past 5-year period.
Looking at the support for the ALHC, a number of firms have released research notes about the stock. Stephens stated their Overweight rating for the stock in a research note on December 03, 2024, with the firm’s price target at $13-$17. BofA Securities was of a view on May 30, 2024 that the stock is Buy, while Robert W. Baird gave the stock Outperform rating on May 30, 2024, issuing a price target of $10. Piper Sandler on their part issued Overweight rating on May 08, 2024.
